相似文献
1
State of the Art and New Perspectives in Lung Cancer Therapeutics.
Cancers (Basel). 2024 Oct 28;16(21):3631. doi: 10.3390/cancers16213631.
2
Arteannuin B Enhances the Effectiveness of Cisplatin in Non-Small Cell Lung Cancer by Regulating Connexin 43 and MAPK Pathway.
Am J Chin Med. 2022;50(7):1963-1992. doi: 10.1142/S0192415X22500847. Epub 2022 Aug 31.
3
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Lung Cancer. 2005 May;48(2):251-61. doi: 10.1016/j.lungcan.2004.10.016. Epub 2004 Dec 15.
4
An extensive review on lung cancer therapeutics using machine learning techniques: state-of-the-art and perspectives.
J Drug Target. 2024 Jul;32(6):635-646. doi: 10.1080/1061186X.2024.2347358. Epub 2024 May 6.
5
Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
Oncol Rep. 2004 Mar;11(3):559-95.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
7
New state of the art in small-cell lung cancer.
Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):8-10.
8
Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.
Drug Des Devel Ther. 2013 Jul 18;7:571-83. doi: 10.2147/DDDT.S46393. Print 2013.
9
Chemotherapy for advanced ovarian cancer: overview of randomized trials.
Semin Oncol. 2000 Jun;27(3 Suppl 7):11-6.
10
Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
BMC Cancer. 2021 Dec 7;21(1):1308. doi: 10.1186/s12885-021-09034-6.
本文引用的文献
1
Cutting-Edge Therapies for Lung Cancer.
Cells. 2024 Mar 1;13(5):436. doi: 10.3390/cells13050436.
2
Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.
Cells. 2023 Oct 4;12(19):2404. doi: 10.3390/cells12192404.
3
Oncolytic virotherapy in lung cancer.
Int Rev Cell Mol Biol. 2023;379:221-239. doi: 10.1016/bs.ircmb.2023.05.004. Epub 2023 May 30.
4
Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy.
Cancers (Basel). 2023 Jul 23;15(14):3733. doi: 10.3390/cancers15143733.
5
Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.
Front Immunol. 2023 May 25;14:1190379. doi: 10.3389/fimmu.2023.1190379. eCollection 2023.
6
Stereotactic Body Radiotherapy for the Management of Early-Stage Non-Small-Cell Lung Cancer: A Clinical Overview.
JCO Oncol Pract. 2023 May;19(5):239-249. doi: 10.1200/OP.22.00475. Epub 2023 Feb 17.
7
Boron Neutron Capture Therapy: Current Status and Challenges.
Front Oncol. 2022 Mar 31;12:788770. doi: 10.3389/fonc.2022.788770. eCollection 2022.
8
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).
Int J Oncol. 2021 Nov;59(5). doi: 10.3892/ijo.2021.5270. Epub 2021 Sep 24.
9
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.
N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.
10
Current role of nanoparticles in the treatment of lung cancer.
J Clin Transl Res. 2021 Mar 16;7(2):140-155. eCollection 2021 Apr 22.
Zotero 插件